RPE65 and retinal degeneration: For example, regarding the biallelic RPE65 mutation, which is the first inherited retinal degeneration with an FDA-approved gene therapy treatment, OCT was shown to identify patients with relative preservation of foveal photoreceptors and hence these patients have a higher likelihood of achieving rescue of central vision with gene therapy [2].